Unlike the SGLT2 inhibitor CVOTs, the improvement in 3-point MACE with numerous GLP-1R agonists does appear to involve attenuation of ischemic heart disease, as trends to decreased rates of nonfatal MI were observed in LEADER (6.0 versus 6.8% event rate; p = 0.11) and SUSTAIN-6 (2.9 versus 3.9% event rate; p = 0.12). This evidence concerns the gene GLP1R and coronary artery disorder.